Metlife (MET) Cash & Equivalents (2009 - 2026)

Metlife's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $11.2 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 0.88% year-over-year to $11.2 billion in Q1 2026; TTM through Mar 2026 was $11.2 billion, a 0.88% decrease from a year earlier, with the FY2025 full-year figure at $22.0 billion, up 85.14% from the prior year.
• Cash & Equivalents slipped to $11.2 billion in Q1 2026 per MET's latest filing, from $22.0 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $23.5 billion in Q1 2022 and bottomed at $1.3 billion in Q4 2022.
• The 5-year median for Cash & Equivalents is $12.0 billion (2024), against an average of $13.5 billion.
• Across the five-year window, Cash & Equivalents slumped 60.83% in 2023 and surged 293.91% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $1.3 billion in 2022, then soared by 134.19% to $3.0 billion in 2023, then jumped by 293.91% to $11.9 billion in 2024, then soared by 85.14% to $22.0 billion in 2025, then sank by 49.16% to $11.2 billion in 2026.
• Per Business Quant, the three latest MET Cash & Equivalents figures stand at $11.2 billion (Q1 2026), $22.0 billion (Q4 2025), and $20.2 billion (Q3 2025).